Apatinib in Refractory Colorectal Cancer

Limited agents have been approved after standard first and second line treatment. Regorafenib and Trifluridine/Tipiracil (TAS-102) are still not approved in China.Apatinib has shown significant efficacy in refractory advanced gastric cancer regarding PFS and OS with controllable toxicity.This study is aimed to explore the efficacy,safety as well as predictive biomarker in advanced colorectal cancer failed to standard therapy in Chinese population.

经标准一线及二线治疗后，可获批的治疗药物极为有限。瑞戈非尼（Regorafenib）与曲氟尿苷替匹嘧啶（Trifluridine/Tipiracil，TAS-102）目前在我国尚未获批。阿帕替尼（Apatinib）在难治性晚期胃癌中展现出针对无进展生存期（Progression-Free Survival, PFS）与总生存期（Overall Survival, OS）的显著疗效，且毒性可控。本研究旨在探索中国人群中经标准治疗失败的晚期结直肠癌患者的治疗疗效、安全性及预测性生物标志物。